Walmart will add GLP-1 medications to its health benefits at no cost to employees, USA Today reported, moving one of the country's largest private employers into the small group of companies fully covering the drugs.

The change matters for HR teams tracking pharmacy spend. GLP-1 drugs such as Ozempic and Wegovy can run above $900 per month without coverage, a cost that has made employers weigh coverage decisions carefully over the past two years. Walmart hasn't disclosed the enrollment numbers or the effective date tied to the expansion in the report.

For a workforce measured in the millions — Walmart employs roughly 1.6 million people in the U.S. — even partial uptake of a high-price drug class shifts plan design math. Benefits leaders elsewhere will watch how Walmart structures the offering: whether it gates access through eligibility criteria, prior authorization or wellness programs.

What does the expansion change for employers?

The decision sets a benchmark. When the largest U.S. private employer covers GLP-1s for free, competitors face sharper questions from their own workers about why coverage is limited or excluded. Recruiters may also find pharmacy benefits becoming a talking point in offer negotiations, particularly in retail and logistics where Walmart competes directly on hourly wages and benefits.

The move also signals confidence that volume purchasing can absorb the cost. Employers who've held back citing budget risk now have a data point from a company operating on similar margins.

What questions should benefits leaders ask?

The report leaves several operational details open, and those details drive cost:

• Which GLP-1 formulations and indications — diabetes, weight loss, or both — the benefit covers
• Whether eligibility requires a BMI threshold, a diagnosed condition or physician attestation
• How Walmart prices the benefit against its existing $1-a-day insulin program introduced in 2021
• What utilization management, if any, applies to refills and duration of treatment

Each of those levers can swing per-member spend by wide margins, benefits consultants have noted across the industry's GLP-1 debates.

Why GLP-1 coverage keeps expanding

Walmart's move follows two years of steady employer interest in the drug class. Surveys including Mercer's have shown a growing share of large employers adding GLP-1 coverage for weight management, though most still restrict it. The medications' list prices have barely moved, which puts pressure on plan sponsors rather than manufacturers.

Walmart also operates its own pharmacy and prescription businesses, including a $4 generic drug program and direct-to-consumer insulin. Offering free GLP-1s to its own employees gives the company a high-visibility demonstration of its healthcare strategy — one it markets to consumers through Walmart Health and its pharmacy counters.

For people-operations teams, the practical takeaway is narrow but real: the largest employer in the U.S. has now priced free GLP-1 coverage into its benefits stack, and employees will notice. Expect the announcement to feed into 2025 and 2026 plan-design conversations as other large employers decide whether to match, restrict or sit out.

By Priya Raman